Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Hong Pan,Wenjun Li,Ze Chen,Yingmei Luo,Wei He,Mengmeng Wang,Xiaofan Tang,Huamei He,Lanlan Liu,Mingbin Zheng,Xin Jiang,Ting Yin,Ruijing Liang,Yifan Ma,Lintao Cai

DOI: https://doi.org/10.1016/j.bioactmat.2020.09.025

IF: 18.9

2021-04-01

Bioactive Materials

Abstract:The adoptive transfer of chimeric antigen receptor-T (CAR-T) cells has shown remarkable clinical responses in hematologic malignancies. However, unsatisfactory curative results and side effects for tumor treatment are still unsolved problems. Herein we develop a click CAR-T cell engineering strategy via cell glycometabolic labeling for robustly boosting their antitumor effects and safety in vivo. Briefly, paired chemical groups (N₃/BCN) are separately incorporated into CAR-T cell and tumor via nondestructive intrinsic glycometabolism of exogenous Ac₄GalNAz and Ac₄ManNBCN, serving as an artificial ligand-receptor. Functional groups anchored on cell surface strengthen the interaction of CAR-T cell and tumor via bioorthogonal click chemistry, further enhancing specific recognition, migration and selective antitumor effects of CAR-T cells. In vivo, click CAR-T cell completely removes lymphoma cells and minimizes off-target toxicity via selective and efficient bioorthogonal targeting in blood cancer. Surprisingly, compared to unlabeled cells, artificial bioorthogonal targeting significantly promotes the accumulation, deep penetration and homing of CAR-T cells into tumor tissues, ultimately improving its curative effect for solid tumor. Click CAR-T cell engineering robustly boosts selective recognition and antitumor capabilities of CAR T cells in vitro and in vivo, thereby holding a great potential for effective clinical cell immunotherapy with avoiding adverse events in patients.

engineering, biomedical,materials science, biomaterials

What problem does this paper attempt to address?

The problem this paper attempts to address is the suboptimal efficacy and side effects of Chimeric Antigen Receptor T-cell (CAR-T) therapy in treating tumors. Specifically, while CAR-T cells have shown significant clinical effects in hematologic malignancies, they still face numerous challenges in the treatment of solid tumors, such as the immunosuppressive effects of the tumor microenvironment and insufficient infiltration and accumulation of CAR-T cells in tumor tissues. Additionally, CAR-T therapy may produce severe on-target/off-target effects, such as the depletion of normal B cells and tumor antigen escape.

To overcome these issues, the authors developed a click chemistry engineering strategy through cell glycometabolism labeling to enhance the antitumor efficacy and safety of CAR-T cells. This strategy involves introducing paired chemical groups (N3/BCN) on the surfaces of CAR-T cells and tumor cells, utilizing bioorthogonal click chemistry to strengthen the interaction between CAR-T cells and tumor cells. This enhances the specific recognition, migration ability, and selective antitumor effects of CAR-T cells. Experimental results indicate that this method not only effectively clears lymphoma cells and reduces off-target toxicity in blood tumor models but also significantly promotes the accumulation, deep penetration, and homing of CAR-T cells in solid tumor tissues, ultimately improving their therapeutic efficacy.